The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Zenith Epigenetics Ltd. and Pfizer Inc. area teaming up in a trial collaboration to evaluate Zenith’s ZEN3694 in combination with the Big Pharma’s talazoparib in patients with locally advanced or metastatic triple negative breast cancer.

ZEN3694 is a bromodomain and extra-terminal domain inhibitor (BETi) in various stages of development for multiple cancers including prostate, breast, head and neck, acute myelogenous leukemia, and B-cell lymphoma. Pfizer’s talazoparib is a poly ADP ribose polymerase inhibitor (PARPi) recently approved for breast cancer. It is also in development for other cancers. In preclinical studies, ZEN3694 with talazoparib showed to be a rational combo therapy to study in patients who are proficient in homologous DNA repair. Combining a BETi and PARPi in those who do not have inherited BRCA gene mutations may significantly increase the potential of PARP inhibition in different indications, initially on triple negative breast cancer. Zenith and Pfizer together will fund and conduct a Phase Ib/II trial starting in Q1 2019. Earlier this month Pfizer penned a trial collaboration with Nektar Therapeutics involving talazoparib.


+ Show All | – Hide All

Financials

There are no financials available.

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Pharmaceuticals
Deal Status Final
Deal Type Alliance
Trial Collaborations
Latest Phase at Time of Deal Marketing
Marketed

Product Information


Click a keyword for comparable deals.

Product 1 of 3
Product Type Pharmaceutical
Generic Name Talazoparib
Brand Name Talzenna
Lab Code MDV3800
Mechanism of Action DNA repair enzyme inhibitor
ADP ribose polymerase 1 inhibitor
ADP ribose polymerase 2 inhibitor
Highest Phase at Time of Deal Marketing
Marketed
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Breast Cancer
Endocrine Cancer
Pancreatic Cancer
Lung Cancer
Renal Cancer
Reproductive System Cancer
Ovarian Cancer
Prostate Cancer
Sarcoma
Clinical Developer Pfizer Inc.

Product 2 of 3
Product Type Pharmaceutical
Lab Code ZEN3694
Mechanism of Action BET protein inhibitor
Highest Phase at Time of Deal Clinical Development
Phase II
Product Therapeutic Area(s) of Focus Cancer
Blood Cancer
Leukemia
Lymphoma
B-Cell Lymphoma
Solid Tumor
Breast Cancer
Head & Neck Cancer
Reproductive System Cancer
Prostate Cancer
Clinical Developer Zenith Epigenetics Ltd.

Product 3 of 3
Product Type Pharmaceutical
Mechanism of Action ADP ribose polymerase 2 inhibitor
ADP ribose polymerase 1 inhibitor
DNA repair enzyme inhibitor
BET protein inhibitor
Highest Phase at Time of Deal Clinical Development
Phase II
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Breast Cancer
Clinical Developer Pfizer Inc.
Zenith Epigenetics Ltd.

Company Information


Click a keyword for comparable companies.

Pfizer Inc. www.pfizer.com | Ticker: PFE
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
NY
Industry Pharmaceuticals
Description Big Pharma
Ownership Public
Therapeutic Area(s) of Focus Cancer
Cardiovascular
Gynecological, Urological
Immune Disorders
Infectious & Viral Diseases
Metabolic Disorders
Musculoskeletal & Connective Tissue Disorders
Neurology, Nervous System
Ophthalmic
Respiratory, Pulmonary

Zenith Epigenetics Ltd. www.zenithepigenetics.com
View Company Profile | View Company Deals
Company Location Worldwide
North America
Canada
Industry Biotechnology
Drug Discovery Tools
Genomics-Proteomics
Pharmaceuticals
Ownership Private
Therapeutic Area(s) of Focus Cancer
Immune Disorders
Alias(es) Zenith Epigenetics Corp.
Alberta Ltd.
RVX Therapeutics Inc.